Japan's Fujifilm starts Avigan trial to treat coronavirus

Tokyo, Japan | AFP | Wednesday 4/1/2020
Japan's Fujifilm has begun clinical trials to test the effectiveness of its anti-flu drug Avigan in treating patients with the new coronavirus, after reports of promising results in China.

(FILES) In this file photo taken on October 22, 2014 anti-influenza Avigan tablets produced by Japan's Fujifilm are displayed in Tokyo. Japan's Fujifilm has begun clinical trials to test the effectiveness of its anti-flu drug Avigan in treating patients with the COVID-19 new coronavirus, after reports of promising results in China. "The trial will be conducted on 100 patients until the end of June 2020," a company spokesman told AFP on April 1, 2020. Kazuhiro NOGI / AFP

Trials in China have suggested Avigan could
play a role in shortening the recovery time for patients infected with coronavirus.
"The trial will be conducted on 100 patients until the end of June," a company spokesman told AFP on Wednesday.
"We will collect data, analyse them and file for approval after that," he added.
The drug will be administered for a maximum of 14 days to coronavirus patients between 20 and 74 years old with mild pneumonia, the spokesman said.
The study excludes pregnant women due to side effects shown in animal testing, he added.
The phase three trial comes after Prime Minister Shinzo Abe said Saturday that the government "will begin the necessary process to formally approve (Avigan) as a treatment against the new coronavirus."
China has already completed clinical trials on favipiravir, the main ingredient in Avigan, the country's ministry of science and technology said last month.

More from this Category:

COMMENT DISCLAIMER: Reader comments posted on this Web site are not in any way endorsed by Manila Standard. Comments are views by manilastandard.net readers who exercise their right to free expression and they do not necessarily represent or reflect the position or viewpoint of manilastandard.net. While reserving this publication’s right to delete comments that are deemed offensive, indecent or inconsistent with Manila Standard editorial standards, Manila Standard may not be held liable for any false information posted by readers in this comments section.